Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
Source: Article title. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case series.
Case series
Describes a group of individual cases.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
Case series · JCEM Case Reports · 2026
Original publication title
A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Immune checkpoint inhibitors enhance antitumor immunologic activity by blocking interaction between inhibitory immune checkpoint receptors. Pembrolizumab blocks the programmed cell death (PD-1) receptor and has been effective in the treatment of many malignancies. While many immune-related endocrinologic adverse effects have been described, immunotherapy-induced hypercalcemia is a rare adverse effect. We present 2 cases of patients who developed pembrolizumab-induced hypercalcemia. Both patients achieved resolution of hypercalcemia with discontinuation of pembrolizumab along with treatment with intravenous fluids, calcitonin, anti-resorptive therapy with either bisphosphonate or denosumab, and glucocorticoid therapy.
These cases demonstrate the importance of recognizing immune checkpoint inhibitors as potential causes of parathyroid hormone (PTH)-independent hypercalcemia.
Authors’ abstract
Abstract
Immune checkpoint inhibitors enhance antitumor immunologic activity by blocking interaction between inhibitory immune checkpoint receptors. Pembrolizumab blocks the programmed cell death (PD-1) receptor and has been effective in the treatment of many malignancies. While many immune-related endocrinologic adverse effects have been described, immunotherapy-induced hypercalcemia is a rare adverse effect. We present 2 cases of patients who developed pembrolizumab-induced hypercalcemia. Both patients achieved resolution of hypercalcemia with discontinuation of pembrolizumab along with treatment with intravenous fluids, calcitonin, anti-resorptive therapy with either bisphosphonate or denosumab, and glucocorticoid therapy.
These cases demonstrate the importance of recognizing immune checkpoint inhibitors as potential causes of parathyroid hormone (PTH)-independent hypercalcemia.
Publication and source details
Original title: A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
Victoria Belcher; Nadia Barghouthi; Sarah Hadique; Hania Woomer; Zeriel Wong; Adnan Haider
JCEM Case Reports · 2026
Correspondence: Adnan Haider, MD, Division of Endocrinology and Metabolism, Department of Medicine, West Virginia University School of Medicine, 1249 Suncrest Towne Center Drive, Morgantown, WV 26505, USA. Email: adnan.haider@hsc.wvu.edu.© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T16:34:11.466967+00:00
DOI: 10.1210/jcemcr/luag042 · PMC13000373